Myos Rens Technology (Myos Rens Technology) Total Current Assets : $2.31 Mil (As of Sep. 2020)

View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Myos Rens Technology's total current assets for the quarter that ended in Sep. 2020 was $2.31 Mil.

Myos Rens Technology Total Current Assets Historical Data

The historical data trend for Myos Rens Technology's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myos Rens Technology Total Current Assets Chart

Myos Rens Technology Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Current Assets

Get a 7-Day Free Trial

3.28

3.82

2.82

2.90

1.76

Myos Rens Technology Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Total Current Assets	Get a 7-Day Free Trial															2.16	1.76	2.40	3.03	2.31

Myos Rens Technology Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Myos Rens Technology's Total Current Assets for the fiscal year that ended in Dec. 2019 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.064	+	0.005	+	1.666	+	0.023
	=	1.76

Myos Rens Technology's Total Current Assets for the quarter that ended in Sep. 2020 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.791	+	0.06	+	1.368	+	0.094
	=	2.31

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Myos Rens Technology (NAS:MYOS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Myos Rens Technology's Liquidation Value for the quarter that ended in Sep. 2020 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.791	-	1.259	+	0.75 * 0.06	+	0.5 * 1.368
=	0.26

Myos Rens Technology Total Current Assets Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Myos Rens Technology (Myos Rens Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927

Website

https://www.myosrens.com

Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.

Executives

Joseph Mannello	director, officer: Chief Executive Officer	C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel	director	PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri	director	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock	director	C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey	director	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne	director	4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas	director	45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte	director	45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin	10 percent owner
John Nosta	director	45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu	director	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren	director, 10 percent owner	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc	10 percent owner	150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd	10 percent owner	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao	director	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019